Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1988-12-28
1990-04-24
Snead, H. M. S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514824, A61K 3156
Patent
active
049201158
ABSTRACT:
Therapeutic amounts of DHEA are administered to human patients for the treatment and prevention of such disorders as atherosclerosis, angina, diabetes, obesity and congestive heart failure. Administering therapeutic quantities of DHEA to human patients has been found to reduce body fat mass and increase muscle mass, lower serum LDL cholesterol levels, lower serum apoB levels, and not affect tissue sensitivity to insulin.
REFERENCES:
patent: 3271250 (1966-09-01), Kanazawa et al.
patent: 3925480 (1975-12-01), Gastambide et al.
patent: 4602008 (1986-07-01), Kreck
patent: 4666898 (1987-05-01), Coleman et al.
patent: 4680289 (1987-07-01), Applezweig
Nestler JE, Barlascini CO, Clore JN, Blackard WG, Dehydroepiandrosterone Reduces Serum Low Density Lipoprotein Levels and Body Fat but does not Alter Inuslin Sensitivity in Normal Men, J. Clin Endocrinol Metab, 66: 57-61, 1988.
Nestler JE, Barlascini CO, Clore JN, Blackard WG, Ginsberg HN, Arad Y: Effect of Dehydroepiandrosterone (DHEA) on Serum Apolipoprotein B (apoB) Levels and Low Density Lipoprotein (LDL), Particle Size in Normal Men, Clin. Res. 37: 22A (Abstracts), 1989.
Nestler JE, Clore JN, Strauss III JF, Blackard WG: The Effects of Hyperinsulinemia on Serum Testosterone, Progesterone, Dehydroepiandrosterone Sulfate, and Cortisol Levels in Normal Women and in a Woman with Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans, J. Clin Endocrinol Metab, 64: 180-184, 1987.
Schwartz AG: Inhibition of Spontaneous Breast Cancer Formation in Femal C3H (A.sup.vy /a) Mice by Long-Term Treatment with Dehydroepiandrosterone, Cancer Res 39: 1129-1132, 1979.
Ben-David M, Dikstein S, Bismuth G, Sulman FG. Anti-Hypercholesterolemic Effect of Dehydroepiandrosterone in Rates, Proc Soc Exp Biol Med, 125; 1136-1140, 1967.
Coleman DL, Leiter EH, Schwizer RW: Theraputic Effects of Dehydorepiandrosterone (DHEA) in Diabetic Mice, Diabetes 31: 830-833.
Coleman, DL, Schwizer RW, Leiter EH: Effect of Genetic Background on the Therapeutic Effects of Dehydroepiandrosterone (DHEA) in Diabetes-Obesity Mutants and in Aged Normal Mice, Diabetes: 33: 26-32 1984.
Parker, Jr. CR, Simpson ER, Bilheimer DW, Leveno K, Carr BR, MacDonald PC: Inverse Relation Between Low-Density Lipoprotein-Cholesterol and Dehydroepiandrosterone Sulfate in Human Fetal Plasma, Science 208: 512-513, 1980.
Barrett-Connor E, Khaw K-T, Yen SSC: A Prospective Study of Dehydroepiandrosterone Sulfate, Mortality and Cardiovascular Disease, N. Eng J Med, 315: 1519-1524, 1986.
Rizza RA, Mandarino LJ, Gerich JE: Dose-Response Characterisitcs for Effects of Insulin on Production and Utilization of Glucose in Man. Am J Physiol 240: E630-E639, 1981.
Morgan CR, Lazarow A: Immunoassay of Insulin: Two Antibody System, Diabetes 12: 115--126, 1963.
Resko JA, Ellinwood WE, Pasztor LM, Buhl AE: Sex Steriods in the Umbilical Circulation of Fetal Rhesus Monkeys from the time of Gonadal Differentiation, J. Clin Endocrinol Metab. 50: 900-905, 1980.
Plymate SR, Fariss BL, Bassett ML, Matej L: Obesity and its Role in Polycystic Ovary Syndrome. J. Clin. Endocrinol Metab 52: 1246-1248, 1981.
Segal P, Bachorik PS, Rifkind BM, Levy RI: Lipids and Dyslipoproteinemia, In: Henry JB (ed), Clinical diagnosis and Management by Laboratory methods, Saunders, Philadelphia, 1984, pp. 180-203.
Kent S: DHEA: "Miracle Drug?", Geriatrics 37: 157-161 1982.
Moordian AD, Morley JE, Korenman SG: Biological Actions of Androgens, Endocr Rev, 8: 1-28, 1987.
Barlascini Cornelius O.
Blackard William G.
Clore John N.
Nestler John E.
Saba James
Snead H. M. S.
Virginia Commonwealth University
LandOfFree
Method of lowering LDL cholesterol in blood does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of lowering LDL cholesterol in blood, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of lowering LDL cholesterol in blood will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-34874